Clinical trials: Liraglutide
PCOS, Obesity
Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on Metformin
The purpose of this study was to determine whether combined treatment with liraglutide and metformin is more effective than liraglutide or metformin as monotherapy in the treatment of obese women with polycystic ovary syndrome…
- Trial name
- NCT01911468
- Testing
- metformin, liraglutide, metformin and liraglutide
- Where
- Slovenia
- Volunteers
- 36 people
- Sponsor
- University Medical Centre Ljubljana
Diabetes Mellitus, Type 1
Liraglutide in Newly Onset Type 1 Diabetes.
The purpose of this study is to investigate the effect and safety of liraglutide 1.8 mg once daily compared to placebo for 52 weeks on change in beta-cell function in patients with newly diagnosed type 1 diabetes as an adjunctive…
- Trial name
- NewLira (NCT01879917)
- Testing
- Liraglutide
- Where
- Denmark
- Volunteers
- 65 people
- Sponsor
- Hvidovre University Hospital
Diabetes, Diabetes Mellitus, Type 2
A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus
This trial is conducted globally. The aim of this trial is to compare efficacy and safety of insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy in combination with metformin in subjects with type 2 diabetes…
- Trial name
- NCT02420262
- Testing
- insulin degludec/liraglutide, insulin glargine, insulin aspart
- Where
- 117 sites in United States, Argentina and 10 more
- Volunteers
- 506 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c
This trial is conducted in North America (the United States of America (USA) and Mexico). The trial is designed to evaluate the effects of treatment with liraglutide versus glimepiride in subjects with type 2 diabetes.
- Trial name
- LEAD-3 (NCT00294723)
- Testing
- liraglutide, glimepiride
- Where
- 117 sites in United States, Mexico and 1 more
- Volunteers
- 746 people
- Sponsor
- Novo Nordisk A/S
Knee Osteoarthritis, Synovitis of Knee
A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis
This phase 2a trial is an international, multicenter, randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of one single intra-articular (IA) injection of 4P004 or placebo in: patients between…
- Trial name
- INFLAM MOTION (NCT07225829)
- Testing
- 4P004
- Where
- 22 sites in United States, Canada and 4 more
- Volunteers
- 130 people
- Sponsor
- 4Moving Biotech
Type 2 Diabetes
Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
The purpose of this study is to determine the optimal dose or doses of HM11260C, when administered once a week under the skin, to improve the control of blood sugar levels in patients with early-stage type 2 diabetes mellitus…
- Trial name
- NCT02057172
- Testing
- HM11260C, liraglutide
- Where
- United States
- Volunteers
- 254 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes
This study is conducted to test the hypothesis that in type 2 diabetic adults with fatty liver who are resistant to metformin, treatment with liraglutide in combination with metformin will cause an absolute reduction in liver fat…
- Conditions
- Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Type 2 Diabetes
- Trial name
- LIRAINS (NCT01399645)
- Testing
- Liraglutide-metformin vs insulin-metformin
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Type 2 Diabetes, Systolic Hypertension
Blood Pressure Outcomes With Liraglutide Therapy
Purpose: The purpose of this study is to further study the mechanism by which liraglutide, a relatively new anti-hyperglycemic medication, might lower blood pressure in patients with Type 2 diabetes and high blood pressure.
- Trial name
- BOLT (NCT01755572)
- Testing
- Liraglutide
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- Mount Sinai Hospital, Canada
Obesity, Weight Loss
Effect of Liraglutide on Microbiome in Obesity
The purpose of the trial is to assess whether the beneficial effect of liraglutide on weight is mediated by changes in the composition of the intestinal Microbiome.
- Conditions
- Obesity, Weight Loss, Microbiome
- Trial name
- NCT04046822
- Testing
- Liraglutide 6 MG/ML [Saxenda]
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- Federico II University
Diabetes Mellitus
Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003)
This study will evaluate the safety, efficacy, and pharmacokinetics of MK-8521 given once daily compared to placebo and another diabetes drug in participants with Type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01982630
- Testing
- MK-8521, Liraglutide
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus
Primary Objective: The primary objective of this study was to assess the dose-response relationship of SAR425899 versus placebo in terms of glycemic control as measured by the change in glycosylated hemoglobin (HbA1c).
- Trial name
- NCT02973321
- Testing
- SAR425899, Liraglutide, Metformin
- Where
- 59 sites in United States, Canada and 6 more
- Volunteers
- 296 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
The Efficacy and Safety of Insulin Degludec/Liraglutide Combination (IDegLira) in Patients With Type 2 Diabetes
The study aims to evaluate the efficacy and safety of IDegLira in type 2 diabetes who have failed premixed insulin therapy. The study plans to enroll 256 participants with inadequate glycemic control despite twice-daily…
- Trial name
- NCT06408532
- Testing
- IDegLira, Premixed insulin
- Volunteers
- 256 people
- Sponsor
- Peking University People's Hospital
Insulin Resistance
The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans
In this research study, investigators will test the effects of an approved medication for diabetes,Liraglutide, to reduce insulin resistance that develops from eating a diet high in saturated fats.
- Trial name
- NCT02403284
- Testing
- Liraglutide, Sugar Pill
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Phoenix VA Health Care System
Diabetes, Diabetes Mellitus, Type 2
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
This trial is conducted in Africa, Asia, Europe and North America. The purpose of the trial is to investigate the effect of insulin degludec (IDeg) in combination with liraglutide (Lira) and metformin (at least 1500 mg daily or…
- Trial name
- NCT01664247
- Testing
- insulin degludec, liraglutide
- Where
- 132 sites in United States, Canada and 9 more
- Volunteers
- 346 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
The purpose of this post approval pragmatic clinical study is to see how well semaglutide lowers body weight compared to other medication on the market used to treat obesity, across three US-based employers.
- Trial name
- NCT05579249
- Testing
- Semaglutide, Orlistat, Phentermine/Topiramate
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes, Type 2 Diabetes
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes
The investigators recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1.
- Trial name
- NCT06976619
- Testing
- Liraglutide Pen Injector, Saline Injections
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Mayo Clinic
Diabetes, Diabetes Mellitus, Type 2
Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India
This study is conducted in Asia. The aim of this study is to evaluate long term safety and efficacy in patients with type 2 diabetes mellitus in routine clinical practice in India.
- Trial name
- NCT03070704
- Testing
- insulin degludec/liraglutide
- Sponsor
- Novo Nordisk A/S
Obesity
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
The purpose of this study is to investigate how the duration of fasting and temporary stopping of Glucagon-Like-Peptide 1 (GLP-1) medications affect the amount of food left in the stomach in people using liraglutide (injected)…
- Trial name
- NCT07225816
- Testing
- Liraglutide, Oral Semaglutide, Semaglutide
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
Obesity Treatment to Improve Diabetes
As the obesity pandemic continues unabated, one can expect to see an increase in the prevalence of TID/T2D and associated CKD. As a result, death will rise, preceded by an increase in kidney failure, requiring dialysis and renal…
- Trial name
- OTID (NCT05390307)
- Testing
- Liraglutide / Semaglutide, Dapagliflozin, Liraglutide or Semaglutide / Dapagliflozin
- Where
- Kuwait
- Volunteers
- 60 people
- Sponsor
- Dasman Diabetes Institute
Weight Loss, Diabetes Mellitus, Type 2
SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.
Introduction: GLP-1 receptor agonists (aGLP1) act increasing pancreatic insulin secretion in response to the glucose, they reduce glucagon secretion and reduce appetite by acting in the central level.
- Conditions
- Weight Loss, Diabetes Mellitus, Type 2, Quality of Life, Safety Issues
- Trial name
- SEVERAL (NCT05136287)
- Testing
- GLP-1 receptor agonist
- Where
- 11 sites in Spain
- Volunteers
- 140 people
- Sponsor
- Jose Seijas Amigo